Sol-Gel Technologies (SLGL) Expected to Announce Earnings on Friday

Sol-Gel Technologies (NASDAQ:SLGL) is expected to announce its Q3 2025 results before the market opens on Friday, November 21st. Analysts expect Sol-Gel Technologies to post earnings of ($2.09) per share and revenue of $0.30 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Friday, November 28, 2025 at 12:30 PM ET.

Sol-Gel Technologies Stock Performance

Shares of SLGL opened at $35.40 on Wednesday. The company’s 50 day simple moving average is $33.70 and its 200 day simple moving average is $19.33. The company has a market capitalization of $98.62 million, a price-to-earnings ratio of -28.78 and a beta of 1.35. Sol-Gel Technologies has a 1 year low of $4.01 and a 1 year high of $52.26.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Wall Street Zen cut shares of Sol-Gel Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Sol-Gel Technologies in a report on Wednesday, October 8th. Zacks Research upgraded Sol-Gel Technologies to a “hold” rating in a report on Tuesday, October 28th. Finally, HC Wainwright increased their target price on Sol-Gel Technologies from $6.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Sol-Gel Technologies has an average rating of “Hold” and a consensus price target of $50.00.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.